المؤلفون: L. Mellars, Kilian Eyerich, C.E. Kleyn, Marc Alexander Radtke, Matthias Augustin, M. Cordey, C. Greggio, Mona Ståhle, V. Koscielny, P.G. Sator, Cem Griffiths, Curdin Conrad, Christine Bundy

المصدر: Journal of the European Academy of Dermatology and Venereology. 35:123-134

مصطلحات موضوعية: medicine.medical_specialty, Dermatology, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Psoriasis Area and Severity Index, Psoriasis, Internal medicine, Severity of illness, Humans, Medicine, Adverse effect, Retrospective Studies, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Dermatology Life Quality Index, medicine.disease, Thalidomide, ddc, Europe, Clinical trial, Cross-Sectional Studies, Treatment Outcome, Infectious Diseases, 030220 oncology & carcinogenesis, Quality of Life, Apremilast, business, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e77920b34fadab9602e336ce7c3cc16
https://doi.org/10.1111/jdv.16431

المؤلفون: Ulrich Mrowietz, O. Sundnes, Alexander Nast, E De Jong, Zsuzsanna Bata-Csorgo, Catherine H. Smith, G. E. van der Kraaij, Paolo Gisondi, Ignacio García-Doval, Marcus Schmitt-Egenolf, Nikhil Yawalkar, K.M. Ronholt, S. Mburu, T. Malkonen, Mariusz Sikora, H Boonen, Satveer K. Mahil, G. Avila Valle, Corinna Dressler, Klaus Strömer, D. Kaur-Knudsen, P.G. Sator, Ph.I. Spuls, Éva Remenyik, Julia-Tatjana Maul, Kristian Reich, D. Trigos

المساهمون: Dermatology, AII - Inflammatory diseases, APH - Methodology, APH - Quality of Care, Experimental Immunology, Graduate School, APH - Personalized Medicine, Department of Dermatology, Allergology and Venereology, HUS Inflammation Center, Helsinki University Hospital Area

المصدر: Nast, A; Smith, C; Spuls, P I; Avila Valle, G; Bata-Csörgö, Z; Boonen, H; De Jong, E; Garcia-Doval, I; Gisondi, P; Kaur-Knudsen, D; Mahil, S; Mälkönen, T; Maul, J T; Mburu, S; Mrowietz, U; Reich, K; Remenyik, E; Rønholt, K M; Sator, P G; Schmitt-Egenolf, M; ... (2021). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris-Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology : JEADV, 35(2), pp. 281-317. Wiley 10.1111/jdv.16926 <http://dx.doi.org/10.1111/jdv.16926>
Nast, A, Smith, C, Spuls, P I, Avila Valle, G, Bata-Csörgö, Z, Boonen, H, De Jong, E, Garcia-Doval, I, Gisondi, P, Kaur-Knudsen, D, Mahil, S, Mälkönen, T, Maul, J T, Mburu, S, Mrowietz, U, Reich, K, Remenyik, E, Rønholt, K M, Sator, P G, Schmitt-Egenolf, M, Sikora, M, Strömer, K, Sundnes, O, Trigos, D, Van Der Kraaij, G, Yawalkar, N & Dressler, C 2021, ' EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2 : specific clinical and comorbid situations ', Journal of the European Academy of Dermatology and Venereology, vol. 35, no. 2, pp. 281-317 . https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venereology
JEADV : Journal of the European Academy of Dermatology and Venereology, 35, 281-317
JEADV : Journal of the European Academy of Dermatology and Venereology, 35, 2, pp. 281-317
Journal of the European Academy of Dermatology and Venereology, 35(2), 281-317. Wiley-Blackwell

مصطلحات موضوعية: medicine.medical_specialty, Tuberculosis, 610 Medicine & health, Disease, Dermatology, Inflammatory bowel disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, Psoriasis, medicine, Humans, Dermatologi och venereologi, 030212 general & internal medicine, Intensive care medicine, Suicidal ideation, business.industry, COVID-19, Guideline, medicine.disease, 3. Good health, Dermatology and Venereal Diseases, Infectious Diseases, 3121 General medicine, internal medicine and other clinical medicine, Concomitant, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], medicine.symptom, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34eded2fefc3a31907400f2d918a637c
https://boris.unibe.ch/164029/1/Acad_Dermatol_Venereol_-_2021_-_Nast_-_EuroGuiDerm_Guideline_on_the_systemic_treatment_of_Psoriasis_vulgaris___Part_2_.pdf

المؤلفون: Franz J. Legat, Robert R. Müllegger, Angelika Hofer, M. Schütz‐Bergmayr, R. Tatarski, Gudrun Ratzinger, Hannes Trattner, Constanze Jonak, Franz Trautinger, Clemens Painsi, K. Wippel‐Slupetzky, Wolfgang Weger, H. Skvara, Martin Inzinger, Thomas Graier, Bernhard Lange-Asschenfeldt, Christine Bangert, Alexandra Gruber-Wackernagel, A. Mlynek, Robert Strohal, N. Häring, Philipp Wolf, C. Kölli, Erich Schmiedberger, Igor Vujic, Sylvia Selhofer, Wolfgang Salmhofer, Adrian Tanew, C. Ellersdorfer, Franz Quehenberger, B. Gruber, K. Prillinger, L. Richter, Matthias Schmuth, W. Saxinger, R. Lichem, Wolfram Hoetzenecker, P.G. Sator

المصدر: The British Journal of Dermatology

مصطلحات موضوعية: medicine.medical_specialty, Epidemiology, Dermatology, Etanercept, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Psoriasis Area and Severity Index, Internal medicine, Ustekinumab, medicine, Adalimumab, Humans, Psoriasis, Registries, Survival rate, Retrospective Studies, Biological Products, business.industry, Original Articles, medicine.disease, Survival Rate, Ixekizumab, Treatment Outcome, Austria, Secukinumab, Female, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7b61960883df8ceec3fcb2ab165f620
https://pubmed.ncbi.nlm.nih.gov/33822355

المؤلفون: P.G. Sator, Ulrich Mrowietz, Ph.I. Spuls, D. Kaur-Knudsen, Alexander Nast, Zsuzsanna Bata-Csorgo, G. E. van der Kraaij, Éva Remenyik, H Boonen, Catherine H. Smith, Julia-Tatjana Maul, Satveer K. Mahil, O. Sundnes, T. Malkonen, Kristian Reich, Marcus Schmitt-Egenolf, S. Mburu, Mariusz Sikora, E.M.G.J. de Jong, D. Trigos, Paolo Gisondi, Ignacio García-Doval, Nikhil Yawalkar, Klaus Strömer, Corinna Dressler, K.M. Ronholt, G. Avila Valle

المساهمون: Department of Dermatology, Allergology and Venereology, Helsinki University Hospital Area, Dermatology, AII - Inflammatory diseases, APH - Methodology, APH - Quality of Care, Experimental Immunology, Graduate School, APH - Personalized Medicine

المصدر: JEADV : Journal of the European Academy of Dermatology and Venereology, 34, 11, pp. 2461-2498
Nast, A, Smith, C, Spuls, P I, Avila Valle, G, Bata-Csörgö, Z, Boonen, H, De Jong, E, Garcia-Doval, I, Gisondi, P, Kaur-Knudsen, D, Mahil, S, Mälkönen, T, Maul, J T, Mburu, S, Mrowietz, U, Reich, K, Remenyik, E, Rønholt, K M, Sator, P G, Schmitt-Egenolf, M, Sikora, M, Strömer, K, Sundnes, O, Trigos, D, Van Der Kraaij, G, Yawalkar, N & Dressler, C 2020, ' EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1 : treatment and monitoring recommendations ', Journal of the European Academy of Dermatology and Venereology, vol. 34, no. 11, pp. 2461-2498 . https://doi.org/10.1111/jdv.16915
Journal of the European Academy of Dermatology and Venereology, 34(11), 2461-2498. Wiley-Blackwell
JEADV : Journal of the European Academy of Dermatology and Venereology, 34, 2461-2498

مصطلحات موضوعية: EUROPEAN ACADEMY, medicine.medical_specialty, education, Brodalumab, S2K GUIDELINE, Dermatology, Severity of Illness Index, Etanercept, HERPES-ZOSTER, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Ustekinumab, medicine, Humans, Psoriasis, SYSTEMIC TREATMENT, Dermatologi och venereologi, 030212 general & internal medicine, Certolizumab pegol, Intensive care medicine, Risankizumab, business.industry, LONG-TERM SAFETY, Adalimumab, LIFE QUALITY INDEX, Guideline, SEVERE PLAQUE PSORIASIS, Infliximab, RHEUMATOID-ARTHRITIS, 3. Good health, Dermatology and Venereal Diseases, Ixekizumab, Infectious Diseases, 3121 General medicine, internal medicine and other clinical medicine, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], ANTITUMOR NECROSIS FACTOR, Secukinumab, business, CLINICAL-TRIALS, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac36a06aaf2073276b6715e3b9ceb28c
https://hdl.handle.net/2066/229416

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.